2/21/2021 · XZ.700 is a chimeric endolysin built combining parts of S. aureus bacteriophage endolysin Ply2638 (Abaev et al. 2013) and Lysostaphin (Sabala et al. 2014). The enzymatic cleavage of the staphylococcal cell wall by XZ.700 is dependent on both the recognition of the cell wall by a cell wall-binding domain (with SH3b homology), and by the specific …
2/21/2021 · In this in vitro study the effect of XZ.700 , a new endolysin , on methicillin resistant Staphylococcus aureus (MRSA) biofilms grown on titanium was evaluated. Biofilms of S. aureus USA300 were grown statically and under flow, and treatment with XZ.700 was compared with povidone-iodine (PVP-I) and gentamicin. To evaluate the cytotoxic effects of XZ.700 and derived biofilm lysates,.
9/22/2020 · XZ.700 is Micreos’ endolysin in pharmaceutical development which targets S. aureus, including the antibiotic-resistant MRSA, while preserving Staphylococcus epidermidis, considered to be …
2/10/2021 · About XZ.700 . Endolysins are cell wall degrading enzymes, derived from naturally occurring phages. XZ.700 is Micreos’ endolysin in pharmaceutical development which targets S. aureus, including the antibiotic-resistant MRSA, while preserving Staphylococcus epidermidis, considered to be beneficial on the skin and conducive to wound healing.
9/22/2020 · XZ.700 is one of several endolysins Micreos has in its portfolio. A structurally similar endolysin , SA.100, is used in the company’s over the counter (OTC) products for inflammatory skin disorders (e.g. acne and rosacea), found in the Gladskin range, which have been on.
8/28/2020 · “With the start of the XZ.700 trial we take the technology to the next level and create tomorrow’s history.” Micreos portfolio also includes a structurally similar endolysin , SA.100, used in over the counter (OTC) products for inflammatory skin ailments, such as acne and rosacea.
4/2/2021 · • XZ.700 is an endolysin targeting S. aureus, including the antibiotic-resistant MRSA, while preserving Staphylococcus epidermidis, that is beneficial on the skin and helps in healing wounds. XZ.700 targets multiple indications including AD, diabetic wound.
Micreos next generation endolysin, XZ.700 , is in clinical development for global registration as a pharmaceutical product. Atopic dermatitis is the first targeted.
XZ.700 is one of several endolysins Micreos has in its portfolio. A structurally similar endolysin , SA.100, is used in the company’s over the counter (OTC) products for inflammatory skin disorders (e.g. acne and rosacea), found in the Gladskin range, which have been on the market since 2013.
11/3/2020 · The company’s endolysin XZ.700 is currently in clinical development and also targets S. aureus with atopic dermatitis identified as the first targeted XZ.700 indication.
